Reviews Bupropion Hydrochloride Extended-Release


No reviews yet.

Wellbutrin XL Drug Description
WELLBUTRIN XL®
(bupropion hydrochloride) Extended-Release Tablets

WARNING
Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN XL or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
XL is not approved for use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®*, WELLBUTRIN SR
and WELLBUTRIN XL are not approved for smoking cessation treatment, but bupropion
under the name ZYBAN®* is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients treated with Bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the post-marketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the pre-marketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many post-marketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as six months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin XL »




WELLBUTRIN XL (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone
hydrochloride. The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN XL is supplied for oral administration as 150-mg and 300-mg, creamy-white
to pale yellow extended-release tablets. Each tablet contains the labeled amount
of bupropion hydrochloride and the inactive ingredients: ethylcellulose aqueous
dispersion, glyceryl behenate, methacrylic acid copolymer dispersion, polyvinyl
alcohol, polyethylene glycol, povidone, silicon dioxide, and triethyl citrate.
The tablets are printed with edible black ink. The insoluble shell of the extended-release
tablet may remain intact during gastrointestinal transit and is eliminated in
the feces.
Last reviewed on RxList: 6/22/2010




Wellbutrin XL Drug Description
WELLBUTRIN XL®
(bupropion hydrochloride) Extended-Release Tablets

WARNING
Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN XL or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
XL is not approved for use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®*, WELLBUTRIN SR
and WELLBUTRIN XL are not approved for smoking cessation treatment, but bupropion
under the name ZYBAN®* is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients treated with Bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the post-marketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the pre-marketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many post-marketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as six months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin XL »




WELLBUTRIN XL (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone
hydrochloride. The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN XL is supplied for oral administration as 150-mg and 300-mg, creamy-white
to pale yellow extended-release tablets. Each tablet contains the labeled amount
of bupropion hydrochloride and the inactive ingredients: ethylcellulose aqueous
dispersion, glyceryl behenate, methacrylic acid copolymer dispersion, polyvinyl
alcohol, polyethylene glycol, povidone, silicon dioxide, and triethyl citrate.
The tablets are printed with edible black ink. The insoluble shell of the extended-release
tablet may remain intact during gastrointestinal transit and is eliminated in
the feces.
Last reviewed on RxList: 6/22/2010




Wellbutrin XL Drug Description
WELLBUTRIN XL®
(bupropion hydrochloride) Extended-Release Tablets

WARNING
Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN XL or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
XL is not approved for use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®*, WELLBUTRIN SR
and WELLBUTRIN XL are not approved for smoking cessation treatment, but bupropion
under the name ZYBAN®* is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients treated with Bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the post-marketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the pre-marketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many post-marketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as six months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin XL »




WELLBUTRIN XL (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone
hydrochloride. The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN XL is supplied for oral administration as 150-mg and 300-mg, creamy-white
to pale yellow extended-release tablets. Each tablet contains the labeled amount
of bupropion hydrochloride and the inactive ingredients: ethylcellulose aqueous
dispersion, glyceryl behenate, methacrylic acid copolymer dispersion, polyvinyl
alcohol, polyethylene glycol, povidone, silicon dioxide, and triethyl citrate.
The tablets are printed with edible black ink. The insoluble shell of the extended-release
tablet may remain intact during gastrointestinal transit and is eliminated in
the feces.
Last reviewed on RxList: 6/22/2010




Wellbutrin XL Drug Description
WELLBUTRIN XL®
(bupropion hydrochloride) Extended-Release Tablets

WARNING
Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN XL or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
XL is not approved for use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®*, WELLBUTRIN SR
and WELLBUTRIN XL are not approved for smoking cessation treatment, but bupropion
under the name ZYBAN®* is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients treated with Bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the post-marketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the pre-marketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many post-marketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as six months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin XL »




WELLBUTRIN XL (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone
hydrochloride. The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN XL is supplied for oral administration as 150-mg and 300-mg, creamy-white
to pale yellow extended-release tablets. Each tablet contains the labeled amount
of bupropion hydrochloride and the inactive ingredients: ethylcellulose aqueous
dispersion, glyceryl behenate, methacrylic acid copolymer dispersion, polyvinyl
alcohol, polyethylene glycol, povidone, silicon dioxide, and triethyl citrate.
The tablets are printed with edible black ink. The insoluble shell of the extended-release
tablet may remain intact during gastrointestinal transit and is eliminated in
the feces.
Last reviewed on RxList: 6/22/2010




Wellbutrin XL Drug Description
WELLBUTRIN XL®
(bupropion hydrochloride) Extended-Release Tablets

WARNING
Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN XL or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
XL is not approved for use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®*, WELLBUTRIN SR
and WELLBUTRIN XL are not approved for smoking cessation treatment, but bupropion
under the name ZYBAN®* is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients treated with Bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the post-marketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the pre-marketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many post-marketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as six months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin XL »




WELLBUTRIN XL (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone
hydrochloride. The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN XL is supplied for oral administration as 150-mg and 300-mg, creamy-white
to pale yellow extended-release tablets. Each tablet contains the labeled amount
of bupropion hydrochloride and the inactive ingredients: ethylcellulose aqueous
dispersion, glyceryl behenate, methacrylic acid copolymer dispersion, polyvinyl
alcohol, polyethylene glycol, povidone, silicon dioxide, and triethyl citrate.
The tablets are printed with edible black ink. The insoluble shell of the extended-release
tablet may remain intact during gastrointestinal transit and is eliminated in
the feces.
Last reviewed on RxList: 6/22/2010





Other reviews about Bupropion Hydrochloride Extended-Release on wordpress

Anchen files ANDA for Wellbutrin XL (buproprion)
  by mais
Anchen files ANDA for Wellbutrin XL (buproprion) Anchen files ANDA for Wellbutrin XL (buproprion) By Lawrence B. Ebert Taiwan-based generic company Anchen Pharmaceuticals has submitted an abbreviated new drug application (ANDA) […]


Wellbutrin XL slightly better than sugar pill - it's official
  by admin
Wellbutrin is an antidepressant - a multiple reuptake inhibitor - it is used to treat depression and to stop smoking (as Zyban). Off label however, it's also used for […]


Federal Agency Approves Use Of Generic Wellbutrin In Depression Patients
  by nitish
The U.S. Food and Drug Administration said Wednesday that a generic version of a popular name brand antidepressant is both safe and effective, despite recent consumer complaintsThe federal […]


GlaxoSmithKline - Products
  by El Horror
About - Every second: Distributes more than 35 doses of vaccine. - Every minute: More than 1,100 prescriptions are written for GSK products. - Every hour: Spends more than $562,000 to […]


Sun Pharma gets US nod for anti-depressant
  by INDOLINK Consulting (es)
The US-based subsidiary of the company has received Food and Drug Administration approval to market its drug Bupropion Hydrochloride Bupropion Hydrochloride Extended-Release, Sun Pharmaceutical said in a filing […]


Caraco Markets Generic Wellbutrin
  by mnroush
Detroit-based Caraco Pharmaceutical Laboratories Ltd. (NYSE Amex: CPD) said Wednesday that it had started shipping bupropion hydrochloride extended release tablets. This product was recently approved by the United States […]


You got some money for us, Ray sa
  by cciyfnpcubzwq
If, however, the tip catches a minute projecting point, the other branches form discs, especially if they find crevices to crawl into. We thought hed like to know […]


So Dorothy sat on the hearthshelf of
  by ikdrqkscrfcy
Mysteries hedged him on all sides, warnings ran before his heavy feet, and countersigns were muttered behind his attentive back. Ill think of it, but mind you, Mac, […]


He picked them up, and wipe
  by thsnebiufjjtet
Well, I must say your boots are in a nice state! Do you remember where I used to keep my bankbook? Why, in the baby, said Rollo, […]


Dont vanish before I get back.
  by dwzgrhwnnrwrxkn
Today Mary Standish was ahead of him at the table. Standing at the edge of the trench, they realized that they had never both gone down together. Well, […]



Other reviews about Bupropion Hydrochloride Extended-Release on web:

Learn about the prescription medication Wellbutrin XL (Bupropion Hydrochloride Extended-Release), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient ... Wellbutrin XL (Bupropion Hydrochloride Extended-Release) Drug ...


PRESCRIBING INFORMATION WELLBUTRIN XL ® (bupropion hydrochloride extended-release tablets) Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to ... WELLBUTRIN XL® (bupropion hydrochloride extended-release tablets)


When switching from bupropion hydrochloride ( Wellbutrin immediate-release, SR, and XL) to ... Wellbutrin XL Extended-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer) Complete Bupropion Hydrochloride information from Drugs.com


Bromhidrato de Bupropion, Tableta oral de liberación prolongada; Bupropion Hydrochloride Oral tablet, extended release 24 hour [Depression/Mood Disorders] bupropion: Definition from Answers.com


Psychiatric Times is the most widely read publication in the field of psychiatry. The Web site features outstanding columnists, compelling features, vital clinical news ... Bupropion Hydrochloride Tablet, Extended Release - Psychiatric Times


Learn about the prescription medication Budeprion XL (Bupropion Hydrochloride Extended-Release Tablets), drug uses, dosage, side effects, drug interactions, warnings, reviews and ... Budeprion XL (Bupropion Hydrochloride Extended-Release Tablets ...


Incidence in Controlled Trials with Bupropion Hydrochloride Extended-Release Tablets (SR) Adverse Events Associated with Discontinuation of Treatment Among Patients Treated with ... Bupropion Side Effects | Drugs.com


Bupropion Hydrochloride Extended-Release Tablets USP (XL) Bupropion Hydrochloride Extended-Release Tablets USP (XL) PRESCRIBING INFORMATION Bupropion hydrochloride extended-release tablets ... bupropion hydrochloride extended-release (er) tablets usp (xl)


1 PRESCRIBING INFORMATION WELLBUTRIN XL ™ (bupropion hydrochloride extended-release tablets) "Patient Information" enclosed. DESCRIPTION WELLBUTRIN XL (bupropion hydrochloride), an ... wellbutrin xl extended-release tablets


... generic bupropion tablets are available in three forms, each as the hydrochloride salt: immediate release (Wellbutrin), sustained release (Wellbutrin SR), and extended release ... Bupropion - Wikipedia, the free encyclopedia





Featured Reviews

Reviews Aminosyn HBC 7% Sulfite Free

Aminosyn HBC 7% Sulfite Free Drug Description AMINOSYN®-HBC 7% Sulfite-Free AN AMINO ACID INJECTION HIGH BRANCHED CHAIN Flexible Plastic Container DRUG DESCRIPTION Aminosyn®-HBC 7%, Sulfite-Free, (an amino acid injection...
Read More  |  Review This
Reviews Nardil

Nardil Drug Description NARDIL® (phenelzine sulfate) Tablets, USP Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents,...
Read More  |  Review This
Reviews Felbamate

Felbatol Drug Description FELBATOL® (felbamate) Tablets 400 mg and 600 mg, Oral Suspension 600 mg/5 mL Before Prescribing Felbatol® (felbamate), the physician should be thoroughly familiar with the details of this prescribing...
Read More  |  Review This
Reviews Altace

Altace Drug Description Altace® (ramipril) Tablets USE IN PREGNANCY When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is...
Read More  |  Review This
Reviews Niacor

Niacor Drug Description NIACOR® (niacin) Tablets,USP 500 mg DRUG DESCRIPTION What are the possible side effects of niacin ? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....